SpeeDx Overview

  • Founded
  • 2009
  • Status
  • Private
  • Employees
  • 92
  • Latest Deal Type
  • Series B
  • Latest Deal Amount
  • $15M
Latest Deal Amount
  • Investors
  • 9

SpeeDx General Information


Developer of a molecular diagnostics test portfolio intended to develop innovative multiplex systems for clinical diagnostics. The company uses real-time polymerase chain reaction technology for multiplex detection and priming strategies, enabling physicians to test infectious disease and antibiotic resistance.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Other Industries
Diagnostic Equipment
Primary Office
  • Suite G16, National Innovation Centre
  • Australian Technology Park, 4 Cornwallis Street, Eveleigh
  • Sydney, New South Wales 2015
  • Australia
+61 (02) 0000 0000

SpeeDx Timeline

Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

SpeeDx Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Later Stage VC (Series B) 11-Feb-2020 $15M 0000 00000 Completed Generating Revenue
8. Later Stage VC 05-Aug-2019 0000 0000 Completed Generating Revenue
7. Later Stage VC (Series A) 23-Apr-2019 000 000 Completed Generating Revenue
6. Grant 04-Sep-2017 00.000 Completed Generating Revenue
5. Accelerator/Incubator Completed Generating Revenue
4. Grant 01-Jul-2016 Completed Generating Revenue
3. Accelerator/Incubator 01-Jan-2015 Completed Generating Revenue
2. Grant 11-May-2014 $1.8M Completed Generating Revenue
1. Early Stage VC Completed Startup
To view SpeeDx’s complete valuation and funding history, request access »

SpeeDx Executive Team (6)

Name Title Board Seat Contact Info
Colin Denver Chief Executive Officer
Bhavin Raval Chief Financial Officer
Elisa Mokany Ph.D Co-Founder & Chief Technology Officer
Alison Todd Ph.D Co-Founder & Chief Scientific Officer
Charles Cartwright Vice President of Scientific Affairs
You’re viewing 5 of 6 executive team members. Get the full list »

SpeeDx Board Members (5)

Name Representing Role Since
Andrew Denver Self Chairman 000 0000
Andrew Jane Self Board Member 000 0000
Bianca Ogden Platinum Asset Management Board Member 000 0000
John Klopp Self Board Member 000 0000
Michael Rubin MD Northpond Ventures Board Member 000 0000
To view SpeeDx’s complete board members history, request access »

SpeeDx Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

SpeeDx Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Platinum Asset Management Asset Manager Minority 000 0000 000000 0
Northpond Ventures Venture Capital Minority 000 0000 000000 0
Global Connections Fund Other 000 0000 000000 0
Springboard Enterprises Accelerator/Incubator Minority 000 0000 000000 0
New South Wales Medical Device Fund Corporation 000 0000 000000 0
You’re viewing 5 of 9 investors. Get the full list »